Charles Caddy Ii, RPA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 485 N Ks Hwy 2, Anthony, KS 67003 Phone: 620-914-1200 Fax: 620-914-1256 |
Mrs. Jo Anne Berry, P.A.-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 1101 E Spring St, Anthony, KS 67003 Phone: 620-842-5144 Fax: 620-842-3372 |
Anna Maria Jennings, PA-C Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 1101 E Spring St, Anthony, KS 67003 Phone: 620-842-5144 |
News Archive
A political deadlock in the Senate has triggered a 21 percent Medicare pay reduction to doctors who say they may have to limit care for older Americans unless the reduction is reversed.
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
Scientists and physicians at Moores Cancer Center at UC San Diego Health, in partnership with colleagues at MD Anderson Cancer Center in Texas, Johns Hopkins University in Maryland and elsewhere, have been awarded a $7 million grant over four years by Stand Up to Cancer to create a "dream team" to develop new ways to prevent pancreatic cancer - one of the nation's deadliest malignancies.
Russian physicists have developed a method for drastically narrowing the emission spectrum of an ordinary diode laser, like that in a laser pointer. This makes their device a useful replacement for the more complex and expensive single-frequency lasers, enabling the creation of compact chemical analyzers that can fit into a smartphone, cheap lidars for self-driving cars, as well as security and structural health monitoring systems on bridges, gas pipelines, and elsewhere.
Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.
› Verified 6 days ago